Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 378

1.

Personalized medicine in oncology: tailoring the right drug to the right patient.

Jiang Y, Wang M.

Biomark Med. 2010 Aug;4(4):523-33. doi: 10.2217/bmm.10.66. Review.

PMID:
20701441
2.

Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.

Pérez-Soler R.

Oncogene. 2009 Aug;28 Suppl 1:S38-45. doi: 10.1038/onc.2009.200. Review.

PMID:
19680295
3.

Personalized oncology: recent advances and future challenges.

Kalia M.

Metabolism. 2013 Jan;62 Suppl 1:S11-4. doi: 10.1016/j.metabol.2012.08.016. Epub 2012 Sep 19. Review.

PMID:
22999010
4.

Recent advances in clinical oncoproteomics.

Jain KK.

J BUON. 2007 Sep;12 Suppl 1:S31-8. Review.

PMID:
17935275
5.

Refocusing the war on cancer: the critical role of personalized treatment.

Potti A, Schilsky RL, Nevins JR.

Sci Transl Med. 2010 Apr 21;2(28):28cm13. doi: 10.1126/scitranslmed.3000643.

PMID:
20410527
6.

Molecular markers in the treatment of metastatic colorectal cancer.

Wilson PM, Labonte MJ, Lenz HJ.

Cancer J. 2010 May-Jun;16(3):262-72. doi: 10.1097/PPO.0b013e3181e07738. Review.

PMID:
20526105
7.

Biomarkers in oncology drug development: rescuers or troublemakers?

Marrer E, Dieterle F.

Expert Opin Drug Metab Toxicol. 2008 Nov;4(11):1391-402. doi: 10.1517/17425255.4.11.1391 . Review.

PMID:
18950281
8.

Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.

McDermott U, Settleman J.

J Clin Oncol. 2009 Nov 20;27(33):5650-9. doi: 10.1200/JCO.2009.22.9054. Epub 2009 Oct 26. Review.

PMID:
19858389
9.

Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist.

Søreide K, Nedrebø BS, Knapp JC, Glomsaker TB, Søreide JA, Kørner H.

Surg Oncol. 2009 Mar;18(1):31-50. doi: 10.1016/j.suronc.2008.06.006. Epub 2008 Jul 30. Review.

PMID:
18672360
10.

Genomics, personalized medicine and cancer practice.

Dancey J.

Clin Biochem. 2012 Apr;45(6):379-81. doi: 10.1016/j.clinbiochem.2012.03.003. No abstract available.

PMID:
22424082
11.

Progress towards personalized medicine.

Bates S.

Drug Discov Today. 2010 Feb;15(3-4):115-20. doi: 10.1016/j.drudis.2009.11.001. Epub 2009 Nov 13. Review.

PMID:
19914397
12.

[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].

Ludwig WD.

Z Evid Fortbild Qual Gesundhwes. 2012;106(1):11-22. doi: 10.1016/j.zefq.2011.12.001. Epub 2012 Jan 10. Review. German.

PMID:
22325103
13.

From genomic landscapes to personalized cancer management-is there a roadmap?

Swanton C, Caldas C.

Ann N Y Acad Sci. 2010 Oct;1210:34-44. doi: 10.1111/j.1749-6632.2010.05776.x.

PMID:
20973797
14.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
15.

Cancer biomarkers: current issues and future directions.

Jain KK.

Curr Opin Mol Ther. 2007 Dec;9(6):563-71. Review.

PMID:
18041667
16.

Genomics and personalized medicine.

Sadee W.

Int J Pharm. 2011 Aug 30;415(1-2):2-4. doi: 10.1016/j.ijpharm.2011.04.048. Epub 2011 Apr 23.

PMID:
21539903
17.

Genomic and personalized medicine: foundations and applications.

Ginsburg GS, Willard HF.

Transl Res. 2009 Dec;154(6):277-87. doi: 10.1016/j.trsl.2009.09.005. Epub 2009 Oct 1. Review.

PMID:
19931193
18.

New science-based endpoints to accelerate oncology drug development.

Kelloff GJ, Sigman CC.

Eur J Cancer. 2005 Mar;41(4):491-501. Epub 2005 Jan 22. Review.

PMID:
15737552
19.
20.

Perspectives of clinical proteomics in gastrointestinal cancer.

Ebert M, Xing X, Burgermeister E, Schmid R, Röcken C.

Expert Rev Anticancer Ther. 2007 Apr;7(4):465-9. Review.

PMID:
17428167

Supplemental Content

Support Center